The future of drug eluting stents

被引：15

作者：

Anis, RR ^{[1
]}

Karsch, KR ^{[1
]}

机构：

[1] Univ Bristol, Bristol Heart Inst, Bristol BS2 8HW, Avon, England

来源：

HEART | 2006年 / 92卷 / 05期

关键词：

D O I：

10.1136/hrt.2005.068288

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In-stent restenosis (ISR) is the major drawback of percutaneous coronary interventions, occurring in 10-40% of patients. Drug eluting stents (DES) are successful in a large majority of patients in preventing restenosis for the first year after implantation. Recently, new stents have emerged that are loaded with anti-inflammatory, antimigratory, antiproliferative, or pro-healing drugs. These drugs are supposed to inhibit inflammation and neointimal growth and subsequently ISR. The future of DES lies in the development of better stents with new stent designs, better polymers including biological polymers and biological biodissolvable stent coatings, and new, better drugs.

引用

页码：585 / 588

页数：4

共 27 条

[1] Tyrphostin AGL-2043 eluting stent reduces neointima formation in porcine coronary arteries [J].

Banai, S ;

Gertz, SD ;

Gavish, L ;

Chorny, M ;

Perez, LS ;

Lazarovichi, G ;

Ianculuvich, M ;

Hoffmann, M ;

Orlowski, M ;

Golomb, G ;

Levitzki, A .

CARDIOVASCULAR RESEARCH, 2004, 64 (01) :165-171

[2]

Bartorelli Antonio L, 2003, J Interv Cardiol, V16, P499, DOI 10.1046/j.1540-8183.2003.01050.x

[3]

BOLAND JL, 2000, INT J CARDIOVASC INT, V3, P215

[4] Stent-based delivery of ABT-578 via a phosphorylcholine surface coating reduces neointimal formation in the porcine coronary model [J].

Collingwood, R ;

Gibson, L ;

Sedlik, S ;

Virmani, R ;

Carter, AJ .

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2005, 65 (02) :227-232

[5]

Di Mario Carlo, 2004, J Interv Cardiol, V17, P391, DOI 10.1111/j.1540-8183.2004.04081.x

[6] Neointimal thickening after stent delivery of paclitaxel: Change in composition and arrest of growth over six months [J].

Drachman, DE ;

Edelman, ER ;

Seifert, P ;

Groothuis, AR ;

Bornstein, DA ;

Kamath, KR ;

Palasis, M ;

Yang, DC ;

Nott, SH ;

Rogers, C .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 36 (07) :2325-2332

[7] Acute and mid-term results of phosphorylcholine-coated stents in primary coronary stenting for acute myocardial infarction [J].

Galli, M ;

Sommariva, L ;

Prati, F ;

Zerboni, S ;

Politi, A ;

Bonatti, R ;

Mameli, S ;

Butti, E ;

Pagano, A ;

Ferrari, G .

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2001, 53 (02) :182-187

[8] Physiological transport forces govern drug distribution for stent-based delivery [J].

Hwang, CW ;

Wu, D ;

Edelman, ER .

CIRCULATION, 2001, 104 (05) :600-605

[9] Stent-based delivery of tissue inhibitor of metalloproteinase-3 adenovirus inhibits neointimal formation in porcine coronary arteries [J].

Johnson, TW ;

Wu, YX ;

Herdeg, C ;

Baumbach, A ;

Newby, AC ;

Karsch, KR ;

Oberhoff, M .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2005, 25 (04) :754-759

[10] Gene delivery from a DNA controlled-release stent in porcine coronary arteries [J].

Klugherz, BD ;

Jones, PL ;

Cui, XM ;

Chen, WL ;

Meneveau, NF ;

DeFelice, S ;

Connolly, J ;

Wilensky, RL ;

Levy, RJ .

NATURE BIOTECHNOLOGY, 2000, 18 (11) :1181-1184

← 1 2 3 →